Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 47.00 | |
10 mg | In stock | $ 89.00 | |
25 mg | In stock | $ 143.00 | |
50 mg | In stock | $ 196.00 | |
100 mg | In stock | $ 330.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 52.00 |
Description | MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary arterial hypertension. MRE-269(ACT-333679) is an active metabolite of Selexipag (S253150). |
Targets&IC50 | IP receptor (human):20 nM(Ki) |
Synonyms | MRE 269, ACT-333679, MRE269 |
Molecular Weight | 419.52 |
Formula | C25H29N3O3 |
CAS No. | 475085-57-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (131.1 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MRE-269 475085-57-5 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor MRE 269 inhibit ACT333679 Inhibitor ACT-333679 MRE269 ACT 333679 inhibitor